Consensus Jazz Pharmaceuticals plc Sao Paulo

Equities

J2AZ34

BRJ2AZBDR009

Market Closed - Sao Paulo Other stock markets 14:17:51 10/05/2024 BST			5-day change	1st Jan Change
38.72 ^BRL	-0.56%		-.--%	-10.95%

06-20	Needham Adjusts Price Target on Jazz Pharmaceuticals to $210 From $222, Maintains Buy Rating	MT
06-20	Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	MT

Evolution of the average Target Price on Jazz Pharmaceuticals plc

Price target over the last 5 years

History of analyst recommendation changes

d.gJPKcVKk9mag-ekQ70QmcqDq5gUlVYoVW0lE8E6nSgo.5cqCGxH0swzJrYRxiDULC8WCqWYTYstAPB8ptCPmHUnk0ag5F-W5OZOrgg~55ac46e59ab0b08b167e840250061bc5

Analyst Recommendations on Jazz Pharmaceuticals plc

Needham Adjusts Price Target on Jazz Pharmaceuticals to $210 From $222, Maintains Buy Rating	06-20	MT
Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing	05-07	MT
UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating	05-03	MT
JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating	03-25	MT
Piper Sandler Adjusts Price Target on Jazz Pharmaceuticals to $188 From $171, Maintains Overweight Rating	03-20	MT
Stifel Raises Jazz Pharmaceuticals' Price Target to $230 From $225, Maintains Buy Rating	03-15	MT
H.C. Wainwright Cuts Price Target on Jazz Pharmaceuticals to $200 From $204, Maintains Buy Rating	03-14	MT
UBS Adjusts Jazz Pharmaceuticals Price Target to $131 From $135, Maintains Neutral Rating	03-01	MT
Barclays Cuts Price Target on Jazz Pharmaceuticals to $230 From $235, Maintains Overweight Rating	03-01	MT
Needham Cuts Price Target on Jazz Pharmaceuticals to $220 From $225, Maintains Buy Rating	02-29	MT
Barclays Adjusts Jazz Pharmaceuticals' Price Target to $235 From $240, Keeps Overweight Rating	01-29	MT
RBC Raises Price Target on Jazz Pharmaceuticals to $195 From $191, Keeps Outperform Rating	01-03	MT
Baird Initiates Jazz Pharmaceuticals With Outperform Rating, Price Target is $160	01-03	MT
UBS Downgrades Jazz Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $135 From $170	11-27	MT
Needham Adjusts Jazz Pharmaceuticals' Price Target to $225 From $226, Maintains Buy Rating	11-09	MT
RBC Cuts Price Target on Jazz Pharmaceuticals to $191 From $200, Keeps Outperform Rating	11-09	MT
Raymond James Initiates Jazz Pharmaceuticals With Market Perform Rating	29/09/23	MT
Cantor Fitzgerald Cuts Jazz Pharmaceuticals' Price Target to $180 From $210, Keeps Overweight Rating	14/08/23	MT
Cantor Fitzgerald Cuts Price Target on Jazz Pharmaceuticals to $180 From $210, Maintains Overweight Rating	14/08/23	MT
RBC Trims Price Target on Jazz Pharmaceuticals to $201 From $203, Keeps Outperform Rating	10/08/23	MT
RBC Lifts Jazz Pharmaceuticals' Price Target to $203 From $202, Keeps Outperform Rating	07/07/23	MT
Needham Adjusts Price Target on Jazz Pharmaceuticals to $212 From $205, Maintains Buy Rating	11/05/23	MT
RBC Cuts Price Target on Jazz Pharmaceuticals to $202 From $207, Notes 'Soft' Q1 Revenue Amid Seasonality, Keeps Outperform Rating	11/05/23	MT
UBS Lowers Jazz Pharmaceuticals' Price Target to $182 From $194, Keeps Buy Rating	11/04/23	MT
RBC Capital Adjusts Jazz Pharmaceuticals Price Target to $207 From $203, Maintains Outperform Rating	06/04/23	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

106.7 USD

Average target price

179.2 USD

Spread / Average Target

+67.86%

High Price Target

230 USD

Spread / Highest target

+115.50%

Low Price Target

117 USD

Spread / Lowest Target

+9.62%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Jazz Pharmaceuticals plc

Needham & Co.
UBS
JPMorgan Chase
Piper Sandler
Stifel Nicolaus
HC Wainwright
Barclays
RBC Capital Markets
Baird
Raymond James
Cantor Fitzgerald
Guggenheim
Goldman Sachs
BofA Securities
Morgan Stanley
SVB Securities LLC
BMO Capital
Truist Securities
SVB Leerink
Citigroup
J.P. Morgan Chase

Ratings for Jazz Pharmaceuticals plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar